In This Section

Program

TUESDAY, MARCH 11

WEDNESDAY, MARCH 12

THURSDAY, MARCH 13

Tuesday, March 11

WELCOME AND OPENING Keynote

5-6:30 p.m. | CME Eligible

  •  5 p.m. | Welcome and Introduction of Keynote Speaker
    Elaine R. Mardis, The Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, Ohio
  • 5:05 p.m. | Keynote
    Keith T. Flaherty, Mass General Cancer Center, Cambridge, Massachusetts
  • 5:45 p.m. | Introduction of Keynote Speaker
    Anthony G. Letai, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 5:50 p.m. | Keynote
    Functional omics for novel therapeutic combinations in myeloid malignancies
    Jeffrey W. Tyner, OHSU Knight Cancer Institute, Portland, Oregon

BREAK

6:30-6:45 p.m.

Plenary Session 1: Functional and Genomic Precision Medicine in Blood Cancers

6:45-8:20 p.m. | CME Eligible

Session Chair: Ann-Kathrin Eisfeld, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • 6:50 p.m.
    Ann-Kathrin Eisfeld
  • 7:20 p.m.
    Sascha Dietrich, University of Düsseldorf, Düsseldorf, Germany
  • 7:50 p.m. 
    R. Coleman Lindsley, Dana-Farber Cancer Institute, Boston, Massachusetts

Opening Reception/poster session a

8:30-10 p.m.

Wednesday, March 12

Continental Breakfast

7-8 a.m.

Plenary Session 2: Functional and Genomic Precision Medicine in Solid Tumors

8-9:35 a.m. | CME Eligible

Session Chair: Peter Horak, German Cancer Research Center, Heidelberg, Germany

  • 8:05 a.m. | Targeting E3 ubiquitin ligases for precision oncology: Functional genomics identifies an ovarian cancer sepcific dependence on CRL4
    Benjamin D. Hopkins, Cornell University, New York, New York
  • 8:35 a.m.
    Jesse S. Boehm, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
  • 9:05 a.m.
    Peter Horak

Break

9:35-9:50 a.m.

Plenary Session 3: Ex vivo patient-derived Models to Identify Biomarkers of Response

9:50-11:25 a.m. | CME Eligible

Session Chair: Alice Soragni, University of California, Los Angeles, California

  • 9:55 a.m.
    David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
  • 10:25 a.m. 
    Alice Soragni
  • 10:55 a.m.
    Chris Jones, The Institute of Cancer Research, Sutton, England

Lunch on own/ Break

11:25 a.m.-1 p.m.

Panel Discussion 1: Regulatory and Non-Regulatory Challenges to the Wide Adoption of Precision Diagnostics

1-2 p.m. | CME Eligible

Session Chair: Anthony G. Letai, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 1:05 p.m.
    Philipp Staber, Medical University of Vienna, Vienna, Austria
  • 1:10 p.m.
    Anthony G. Letai
  • 1:15 p.m.
    Keith L. Ligon, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 1:20 p.m. | Panel Discussion

Plenary Session 4: Vertebrate Models for Modeling Disease and Guiding Therapy

2:15-3:50 p.m. | CME Eligible

Session Chair: Genevieve C. Kendall, The Ohio State University, Nationwide Children’s Hospital, Columbus, Ohio

  • 2:20 p.m.
    Genevieve C. Kendall
  • 2:50 p.m.
    Álvaro Curiel-García, Columbia University Irving Medical Center, New York, New York
  • 3:20 p.m. | Single mouse testing (SMT): An alternative approach to encompass clinical heterogeneity of pediatric cancers
    Peter J. Houghton, UT Health Science Center at San Antonio, San Antonio, Texas

Break

3:50-4 p.m.

Plenary Session 5: Challenges of Intra-Tumor and Intra-Patient Heterogeneity for Precision Medicine

4-5:35 p.m. | CME Eligible

Session Chair: Elaine R. Mardis, The Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, Ohio

  • 4:05 p.m.
    Paul C. Boutros, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
  • 4:35 p.m.
    Elaine R. Mardis, The Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, Ohio
  • 5:05 p.m.
    Scott R. Manalis, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

Panel Discussion 2: Challenges in Tissue Acquisition and Handling for Precision Medicine

5:40-6:40 p.m. | CME Eligible

Session Chair: Alice Soragni, University of California, Los Angeles, California

  • Peter Horak, German Cancer Research Center, Heidelberg, Germany
  • Benjamin D. Hopkins, Cornell University, Larchmont, New York
  • Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas

Lightning lectures

6:45-7:15 p.m.

Poster Session b/ Reception

7:15-8:45 p.m.

Thursday, March 13

Continental Breakfast

7-8 a.m.

Plenary Session 6: New Omics for Precision Medicine

8-9:35 a.m. | CME Eligible

Session Chair: Thomas Kislinger, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

  • 8:05 a.m.
    Bernhard Küster, Technical University of Munich, Freising, Germany
  • 8:35 a.m. | Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
    Thomas Kislinger
  • 9:05 a.m.
    M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

Break

9:35-9:50 a.m.

Plenary Session 7: Machine Learning to Integrate Multiple Data Layers

9:50 a.m. | CME Eligible

Session Chair: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 9:55 a.m.
    Taran Gujral, Fred Hutchinson Cancer Center, Seattle, Washington
  • 10:25 a.m.
    Casey Greene, University of Colorado Anschutz Medical Campus, Aurora, Colorado
  • 10:55 a.m.
    Eliezer M. Van Allen

Break / Box Lunches Available

11:25 a.m.-12 p.m.

Plenary Session 8: Immunotherapy-predictive Biomarkers

12-1:35 p.m. | CME Eligible

Session Chair: Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 12:05 p.m.
    Patricia Perez-Galan, IDIBAPS Barcelona, Spain
  • 12:35 p.m..
    Padmanee Sharma
  • 1:05 p.m.
    Anne Rios, Princess Maxima Center for Pediatric Oncology, CS Utrecht, The Netherlands

Break

1:35-1:50 p.m.

Plenary Session 9: Clinical Trial Design for Optimal Implementation of Precision Medicine

1:50-3:25 p.m. | CME Eligible

Session Chair: Philipp Staber, Medical University of Vienna, Vienna, Austria

  • 1:55 p.m. 
    Philipp Staber
  • 2:25 p.m. 
    Candace M. Howard-Claudio, University of Mississippi Medical Center, Jackson, Mississippi                                
  • 2:55 p.m.
    Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Closing Remarks

3:25 p.m.